Based on data from 1, 070 patients with DLBCL, the model demonstrated that Ki‐67 expression level can serve as an independent prognostic factor in multivariate analysis, particularly in patients receiving R‐CHOP or similar regimens, providing better predictive efficacy for high‐risk patients than the traditional International Prognostic Index (IPI).12 This evidence concerns the gene MKI67 and diffuse large B-cell lymphoma.